- Home
- MDRR vs NCEL Comparison
MDRR vs NCEL Comparison
Compare MDRR & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDRR | NCEL |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | Switzerland |
| Employees | N/A | 11 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 13.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MDRR | NCEL |
|---|---|---|
| Price | $11.56 | $2.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.1K | ★ 17.2K |
| Earning Date | 11-06-2025 | 04-10-2026 |
| Dividend Yield | ★ 2.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.55 | $1.89 |
| 52 Week High | $14.52 | $4.70 |
Technical Indicators
Market Signals| Indicator | MDRR | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 36.99 |
| Support Level | $11.48 | $2.44 |
| Resistance Level | $12.49 | $3.16 |
| Average True Range (ATR) | 0.33 | 0.16 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 41.08 | 0.00 |
Price Performance
Historical ComparisonAbout MDRR Medalist Diversified REIT Inc.
Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.
About NCEL NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.